SCHEMBL26424285

SCHEMBL26424285

CCCCONC(=O)CCC(Cc1ccc(C(=O)OC(C)(C)C)cc1)C(=O)OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.42
TSHR P16473 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPK1 P28482 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
FOLH1 Q04609 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SYK P43405 1/20 0.39
GAA P10253 1/20 0.39
RAB9A P51151 1/20 0.39
KMT2A Q03164 1/20 0.39
EPHX2 P34913 2/20 0.38
PPARG P37231 2/20 0.38
SLC7A5 Q01650 1/20 0.37
ITGB3 P05106 1/20 0.37
ITGA2B P08514 1/20 0.37
ENPP2 Q13822 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23710339 0.92 FOLH1 (0.45) LTA4HCYP3A4TDP1FOLH1SYK
SCHEMBL26424287 0.89 FOLH1 (0.50) LTA4HTSHRALDH1A1CYP3A4MAPK1
SCHEMBL26424302 0.83 SLC7A5 (0.45) ALDH1A1CYP3A4TDP1SYKGAA
SCHEMBL23704724 0.83 CPA3 (0.49) ALDH1A1CYP3A4TDP1FOLH1SYK
SCHEMBL14534741 0.81 ALDH1A1 (0.46) TSHRALDH1A1CYP3A4MAPK1TDP1
SCHEMBL14534518 0.80 ALDH1A1 (0.41) LTA4HTSHRALDH1A1CYP3A4MAPK1
SCHEMBL26427168 0.79 LTA4H (0.42) LTA4HFOLH1SYKRAB9AKMT2A
SCHEMBL20179243 0.79 FOLH1 (0.42) LTA4HFOLH1RAB9ASLC7A5
SCHEMBL23704713 0.78 FOLH1 (0.55) LTA4HFOLH1RAB9AEPHX2PPARG
SCHEMBL23710397 0.77 L3MBTL1 (0.38) ALDH1A1CYP3A4TDP1L3MBTL1SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230128984-A1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230128984-A1 BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) SLC10A2, GPBAR1, NR1H4 LTA4H 1295/4885TSHR 4740/4885ALDH1A1 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.